Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Merrem Iv

(Meropenem I.V. 2g as a 3 hour infusion every 8 hours)

Small molecule

BB. Braun Medical Inc.

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

3

FDA Applications

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Antibiotics1 trial

Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients

Active, not recruiting·—·Phase 1/2·NCT07096310·400 enrolled

Regulatory

FDA Approval Timeline[3]

Jun 21, 1996

MERREM IV

NDA NDA050706

Apr 30, 2015

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

NDA NDA202106

Jul 26, 2023

MEROPENEM

NDA NDA215212

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meropenem I.V. 2g as a 3 hour infusion every 8 hours. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meropenem I.V. 2g as a 3 hour infusion every 8 hours compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA215212). U.S. Food & Drug Administration.
[4]
SEC EDGAR — B. Braun Medical Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BB. Braun Medical Inc.

Related News